oa SA Pharmaceutical Journal - Galvus® (vildagliptin) : South Africa's first DPP-4 inhibitor : new product focus : drug info

Volume 78, Issue 3
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Galvus® (vildagliptin) is a new oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Vildagliptin is approved for use as add-on therapy in patients taking metformin, a sulphonylurea or insulin.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error